0ET Stock Overview
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Esperion Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.81 |
| 52 Week High | US$2.99 |
| 52 Week Low | US$0.67 |
| Beta | 0.82 |
| 1 Month Change | -21.41% |
| 3 Month Change | -3.75% |
| 1 Year Change | 84.06% |
| 3 Year Change | -91.97% |
| 5 Year Change | -95.12% |
| Change since IPO | -90.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0ET | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 18.0% | 2.3% | 0.5% |
| 1Y | 84.1% | -28.6% | 1.3% |
Return vs Industry: 0ET exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 0ET exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| 0ET volatility | |
|---|---|
| 0ET Average Weekly Movement | 15.3% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0ET's share price has been volatile over the past 3 months.
Volatility Over Time: 0ET's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 240 | Sheldon Koenig | www.esperion.com |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.
Esperion Therapeutics, Inc. Fundamentals Summary
| 0ET fundamental statistics | |
|---|---|
| Market cap | €376.07m |
| Earnings (TTM) | -€195.06m |
| Revenue (TTM) | €108.45m |
3.5x
P/S Ratio-1.9x
P/E RatioIs 0ET overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0ET income statement (TTM) | |
|---|---|
| Revenue | US$116.33m |
| Cost of Revenue | US$129.37m |
| Gross Profit | -US$13.04m |
| Other Expenses | US$196.21m |
| Earnings | -US$209.25m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -1.10 |
| Gross Margin | -11.21% |
| Net Profit Margin | -179.87% |
| Debt/Equity Ratio | -117.9% |
How did 0ET perform over the long term?
See historical performance and comparison